Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer

• Status: Completed
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the feasibility and toxicity of neoadjuvant hypofractioned radiotherapy concurrently with weekly gemcitabine and an EGFR tyrosine-kinase inhibitor (OSI-774, Tarceva) in the treatment of patients with resectable pancreatic cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Indiana University School of Medicine
• Collaborator: Genentech, Inc.
• Treatments: Erlotinib Hydrochloride

Criteria

Inclusion Criteria:

• pathologically confirmed adenocarcinoma of the pancreas

• resectable disease

• tumor
• ECOG performance 0-1

• Organ system fxn: granulocytes (>/=1800/uL); plt ct >/=100K; bili<2.5ULN; crt
• Normal CXR

• Negative pregnancy test

Exclusion Criteria:

• metastatic disease or peritoneal seeding based on cross-sectional imaging

• previous irradiation to the planned field

• prior chemotherapy or immunotherapy

• active infection

• active PUD